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Abstract
Background: Aberrant DNA methylation patterns might be used as a biomarker for diagnosis and management of cancer
patients.
Methods and Findings: To achieve a gene panel for developing a breast cancer blood-based test we quantitatively assessed
the DNA methylation proportion of 248 CpG sites per sample (total of 31,248 sites in all analyzed samples) on 10 candidate
genes (APC, BIN1, BMP6, BRCA1, CST6, ESR-b, GSTP1, P16, P21 and TIMP3). The number of 126 samples consisting of two
different cohorts was used (first cohort: plasma samples from breast cancer patients and normal controls; second cohort:
triple matched samples including cancerous tissue, matched normal tissue and serum samples). In the first cohort,
circulating cell free methylated DNA of the 8 tumor suppressor genes (TSGs) was significantly higher in patients with breast
cancer compared to normal controls (P,0.01). In the second cohort containing triple matched samples, seven genes
showed concordant hypermethylated profile in tumor tissue and serum samples compared to normal tissue (P,0.05). Using
eight genes as a panel to develop a blood-based test for breast cancer, a sensitivity and specificity of more than 90% could
be achieved in distinguishing between tumor and normal samples.
Conclusions: Our study suggests that the selected TSG panel combined with the high-throughput technology might be a
useful tool to develop epigenetic based predictive and prognostic biomarker for breast cancer relying on pathologic
methylation changes in tumor tissue, as well as in circulation.
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Introduction
Breast cancer is one of the most common types of cancer among
women. Localized breast cancer at an early stage has better
prognosis and requires less severe treatment with a survival rate of
98% [1]. However, diagnosis after tumor metastasis lowers the
survival rate to 27% [2]. This highlights the importance of early
breast cancer detection which is dependent on sensitive and specific
screening methods. The traditional triple test for breast cancer
diagnosis includes physical examination, mammography and
aspiration cytology. Unfortunately, all these methods are not
sensitive enough in identifying breast cancer in early stages [1,3].
A minimally invasive screening test beside the triple test, or prior to
biopsy, would lead to greater sensitivity.
It is well recognized that solid malignant tumors release
significant amounts of DNA into the systemic circulation through
cellular necrosis or apoptosis [4]. The presence of cell-free DNA
(cfDNA) in plasma and serum has been known for over 60 years.
Quantitative alteration of circulating cfDNA has been observed in
several cancers, such as prostate cancer [5], lung cancer [6],
pancreatic cancer [7], and breast cancer [8]. The tumor released
DNA in circulation might serve as biomarker for cancer [8].
Aberrant promoter methylation pattern of tumor suppressor genes
(TSGs) is known to be a frequent and early event in carcinogenesis
[9,10,11,12]. Tumor-specific methylated DNA alterations have been
found in the circulation of patients with different types of cancer
[12,13]. The analysis of the methylation patterns of cfDNA by a
blood-based test might enable to distinguish between benign and
malignant tumors for diagnosis and surveillance of patients [12].
The SEQUENOM’s EpiTYPER
TM assay is a high-throughput
methylation quantification method which relies on matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS) [14]. The sensitivity, specificity and assay
concept of the method have been previously described by ulterior
studies [14,15,16,17,18,19,20]. Recently, we analyzed the methyl-
ation profiles of more than 42,528 CpG sites on 22 genes of which
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e1608010 were shown to be hypermethylated genes (APC, BIN1, BMP6,
BRCA1, CST6, ESR-b, GSTP1, P16, P21 and TIMP3) in cancerous
breast tissue in comparison with matched normal tissue [17]. These
10 hypermethylated geneswereconsidered asmethylationsignature
ofbreast cancerandwereused inthisstudyforfurtherinvestigations
to develop an epigenetic blood-based assay for breast cancer.
In the present study, to achieve a reliable gene panel for
developing a blood-based test, we quantitatively assessed the DNA
methylation profile of 10 breast cancer candidate genes using
MALDI-TOF MS in two different cohorts of patients with breast
cancer on large-scale CpG sites.
Materials and Methods
The study was performed at the Laboratory for Gynecological
Oncology, Department of Biomedicine, Women’s Hospital, Basel
and approved by the local institutional review board (Ethic
commission beider Basel). Written consent forms were collected
from all patients who were involved in this study.
Sampling and pathological classification
In total 126 samples were used in this study. For analysis we
divided these samples in two different cohorts. The first cohort
consisted of 36 plasma samples of breast cancer patients and 30
plasma samples of healthy non-relative women. The second cohort
consisted of 60 triple samples (cancerous tissue, matched normal
tissue and serum samples) from 20 patients with non-familial
breast cancer. Staging and grading was evaluated according to the
WHO histological classification. Breast cancer characteristics, such
as staging, histological grading, and hormone receptor expression
from the two different cohorts are summarized in Table 1.
Isolation of circulating cfDNA from plasma and serum
A total of 20 mL blood samples were collected in both EDTA
tubes (for plasma) and EDTA-free tubes (for serum) and processed
immediately after collection. The plasma samples were centrifuged
at 1,6006g (10 min), and supernatant was carefully transferred
into 2 mL microtubes. Samples were centrifuged in a microcen-
trifuge at full speed (10 min), and supernatants were stored at
280uC until analysis was performed. The serum tubes were
coagulated during approximately 1h, after which the serum was
harvested and stored using the above mentioned procedure.
DNA extraction was performed from 25–50 mg of frozen tissue
and 600 mL of plasma and serum using the High Pure PCR
Template Preparation Kit (Roche Diagnostics, Mannheim,
Germany) and eluted in a final volume of 100 mL. The median
Table 1. Clinical characteristics of patients in the two study cohorts.
Sample
type
Total
no. of
patients
Age mean
± S.D.
(range) Pathologic stage
No. of
patients with
lymph node
involvement
No. of
patients
with
metastasis
Histological
grade ER PR
Early* Late** 1 2 3 Positive Negative Positive Negative
Plasma
samples
36 67613.4
(38–89)
27 9 19 0 11 18 7 28 8 23 13
Triple
samples
20 50611.7
(33–77)
12 8 13 0 0 5 15 16 4 10 10
*The pathologic stage,III was considered as ‘‘Early stage’’.
**The pathologic stage III and IV was considered as ‘‘Late stage’’.
ER: Estrogen receptor; PR: Progesterone receptor.
doi:10.1371/journal.pone.0016080.t001
Table 2. High-throughput methylation analysis of CpG sites per amplicon for the 10 studied genes.
Genes
Amplicon
size (bp)
Total No.
of CpG sites
in amplicon
No. of
analyzed CpG
sites in amplicon
No. of informative
CpG sites
in amplicon No. of analyzed CpG sites per amplicons
Single sites Composite sites
APC 4 2 0 2 6 1 81 21 26
BIN1 3 3 0 3 2 1 81 23 1 5
BMP6 397 37 30 9 11 19
BRCA1 413 30 15 7 10 5
CST6 445 49 27 6 15 12
ESR-b (ER beta) 3 7 4 3 0 2 4 671 7
GSTP1 381 23 17 8 10 7
P16 (CDKN2A) 5 8 0 6 2 3 61 41 32 3
P21 (CDKN1A) 419 30 19 8 10 9
TIMP3 4 4 1 5 1 4 41 41 13 3
The in silico digestion was performed for the T-cleavage assay. The percentage of total CpG sites in the amplicon is divided into single sites (single CpG sites) and
composite sites (two or more adjacent CpG sites fall within one fragment, or when fragment masses are overlapping).
doi:10.1371/journal.pone.0016080.t002
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(range 2.6 to 12.1) and 7.1 ng/mL (range 5.4 to 14.8) respectively.
The median quantity of extracted DNA from frozen tissue was
65.7 ng/mL (range 28.3 to 186.1).
Before performing the methylation analysis, we quantified the
yield of extracted DNA by quantitative PCR for the GAPDH
(glyceraldehyde 3-phosphate dehydrogenase) gene. The good
quality of the extracted DNA allowed successful amplification
and quantification of the GAPDH gene in all samples (data not
shown).
Bisulfite Treatment
To perform bisulfite conversion of the target sequence, the
EpitectH Bisulfite Kit (QIAGEN AG, Basel, Switzerland) was used
according to the manufacturer’s protocol.
Primer design and PCR-tagging for EpiTYPER
TM assay
We used previously designed and tagged primers (reverse
primer with T7-promoter tag and forward primer with 10mer tag
sequence as balance) for the 10 candidate genes [17]. Selected
amplicons were mostly located in the promoter regions, or started
from the promoter and partially covered the first exon [17]. For
the PCR on bisulfite-treated genomic DNA (gDNA), the following
PCR conditions were used: 16:9 5 uC for 10 min; 486:9 5 uC for
30s, Ta for 40s, 72uC for 1 min; 16 72uC for 5 min. The PCR
cocktail was: 2mL DNA (2.00mL of at least 10 ng/mL DNA for a
final concentration of 2ng/mL per reaction) in a 10mL total volume
using 1pmol of each primer, 200mM dNTP, 0.2 unit Hot Start
Taq DNA polymerase, 1.5mM MgCl2 and the buffer supplied
with the enzyme.
In vitro transcription and T-cleavage assay
In vitro transcription and T-cleavage assay were assessed
according to the previously published methods [14,16,17]. Briefly,
unincorporated dNTPs were removed by shrimp alkaline
phosphatase (SAP; SEQUENOM, Inc., San Diego, CA) treat-
ment. Typically, 2 mL of the PCR product were used as template
for the transcription reaction. Twenty units of T7 R&DNA
polymerase (Epicentre, Madison, WI) were used to incorporate
dTTP in the transcripts. Ribonucleotides and dNTPs were used at
concentrations of 1 mmol/L and 2.5 mmol/L, respectively. In the
same step, RNase-A (SEQUENOM Inc., San Diego, CA) was
added to cleave the in vitro transcripts (T-cleavage assay). Samples
were diluted with H2O to a final volume of 27 mL. Conditioning of
the phosphate backbone was achieved by adding 6 mg of Clean
Resin (SEQUENOM) before performing MALDI-TOF MS
analysis.
Mass spectrometry
Twenty-two nanoliters of the RNase-A treated product were
robotically dispensed onto silicon matrix preloaded chips (Spectro-
CHIP; SEQUENOM, San Diego), the mass spectra were collected
using a MassARRAYH Compact MALDI-TOF (SEQUENOM)
and spectra’s methylation proportion were generated by the
EpiTYPER
TM software v1.0 (SEQUENOM, San Diego).
Statistical methods
Data analysis was performed using the PASW Statistics software
v.18. The Shapiro-Wilk and Kolmogorov-Smirnov tests were used
for data distribution analysis. Both tests similarly demonstrated
that our data set was not normally distributed (Shapiro-Wilk test;
P,0.001 and Kolmogorov-Smirnov test; P,0.001). Quantitative
methylation proportion of 10 genes was analyzed in two different
study cohorts. Using two-way hierarchical cluster analysis, the
most variable CpG sites for each gene were clustered based on
pair-wise Euclidean distances and linkage algorithm for all studied
samples according to the previously developed method by Gene
Expression Statistical System (GESS) version 7.1.19 (NCSS,
Kaysville, Utah, USA) [16,17,18]. The Mann-Whitney U test
was used to compare the promoter methylation between study
groups and also with clinicopathological parameters. The non-
parametric Spearman’s rho test was used to find out the
correlation of methylation proportion in serum versus tumor and
normal samples. Three dimensional principal component analysis
(PCA) was accessed for both different cohorts based on the
methylation proportion of 10 studied genes to transform a number
of possibly correlated variables into a smaller number of
uncorrelated variables.
Results
Quantitative methylation profiling of the 10 studied
genes
In this study, we analyzed the methylation proportion of 10
breast cancer candidate genes in 126 different samples consisting
of two different cohorts (36 plasma samples from patients with
breast cancer and 30 plasma samples from normal controls, as well
as 60 triple matched samples containing cancerous tissue, normal
tissue and serum from 20 breast cancer patients). For all of the
studied genes one amplicon per gene was analyzed and all
amplicons contained CpG rich islands (with the number of CpG
sites higher than 20) (Table 2). In total, we assessed 10 amplicons,
containing 248 CpG sites per sample (total of 31,248 sites in all
analyzed samples) (Table 2; Fig. 1; Dataset S1). From several
analyzed CpG sites per amplicon few of them could represent
valuable differences in the studied cases which were considered as
informative CpG sites (Table 2). The mean methylation quantity
of the informative CpG sites per each gene was used to figure out
the methylation proportion of the candidate genes (Dataset S1).
Methylation proportion of candidate genes in plasma
samples. Methylation proportion of each CpG site is given on a
scaling 0 to 100 percent. Using two-way hierarchical cluster
analysis, we found different methylation pattern of the candidate
genes in plasma samples between patients with breast cancer and
normal controls (Fig. 1; Dataset S1). Cell free methylated DNA
levels of 8 genes (APC, BIN1, BRCA1, CST6, GSTP1, P16, P21 and
TIMP3) were significantly higher in the plasma samples from
patients with breast cancer in comparison with those from normal
controls (P,0.01), while the other two genes BMP6 and ESR-b
showed the same tendency but was not significant (P.0.05)
(Fig. 2a; Dataset S1). PCA mapping based on the mean
Figure 1. Methylation profiling of 10 candidate genes in two studied cohorts. A) An example of high-throughput methylation analysis of
CpG sites for the BRCA1 gene for the 60 triple samples (cancerous tissue, matched normal tissue and serum samples). The complete data for the other
genes is summarized in Dataset S1. B) Peaks show percentage of methylation extent obtained from an informative CpG site of BRCA1 gene with a
significant difference between serum and tumor with normal tissue in a triple case. C) Double dendrogram profiles the mean methylation proportion
of all 10 studied genes in plasma samples from breast cancer patients and normal subjects. D) Double dendrogram profiles the mean methylation
proportion of all 10 studied genes in triple matched samples. E) PCA mapping of the mean methylation proportion of analyzed genes in plasma
samples. F) PCA mapping of the mean methylation proportion of analyzed genes in triple matched samples.
doi:10.1371/journal.pone.0016080.g001
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samples showed a number of possibly correlated samples into a
smaller number of uncorrelated samples (Fig. 1E).
Methylation proportion of candidate genes in triple
matched samples. To confirm that hypermethylation of cell
free DNA in circulation of breast cancer patients are derived from
tumor tissue, triple matched samples including cancerous tissue,
matched normal tissue and serum samples were analyzed.
Hierarchical clustering showed significant hypermethylation
patterns for serum and tumor tissue compared with normal
tissue for seven genes (APC, BIN1, BMP6, BRCA1, CST6, P16 and
TIMP3). The GSTP1 gene was significantly hypermethylated in
Figure 2. Comparison between quantitative methylation analyses of 10 candidate genes. A) Thirty six plasma samples of breast cancer
patients and 30 plasma samples of normal subjects as control. B) Triple matched samples from 20 breast cancer patients. (* significant difference;
Mann-Whitney U Test).
doi:10.1371/journal.pone.0016080.g002
Figure 3. ROC curve analysis using cfDNA for discriminating between cancerous and normal samples based on methylation
patterns of 10 candidate genes. A) ROC curves of cfDNA to discriminate between plasma sample of breast cancer patients and plasma samples of
normal subjects. B) ROC curves of cfDNA to discriminate between serum with and matched normal tissue samples.
doi:10.1371/journal.pone.0016080.g003
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samples compared to the normal tissue. For the ESR-b gene no
significant differences in the methylation extent was observed
between studied groups (Fig. 2b). PCA mapping based on the
mean methylation proportion of seven genes in the cohort of triple
matched samples showed a number of possibly correlated samples
into a smaller number of uncorrelated samples (Fig. 1F).The
complete methylation quantification data for 10 studied genes is
summarized in dataset S1.
A correlation study of the methylation proportion of DNA in
serum versus cancerous and normal breast tissue revealed a
correlation between tumor tissue and serum for BMP6, BRCA1,
CST6, GSTP1, P16 and TIMP3 genes but not with the matched
normal tissue (Dataset S2).
Sensitivity and specificity of a blood based assay to
distinguish tumor derived hypermethylated DNA with
non-hypermethylated DNA
To find a reliable gene panel which could serve as sensitive and
specific blood-based methylation test, gene coverage analysis was
assessed for 8 genes with significant different methylation pattern
between cancerous and normal plasma. To evaluate the
applicability of circulating cfDNA as a biomarker for breast
cancer, receiver operating characteristic (ROC) curve analysis was
used. Cut-off points, sensitivity, area under the curve (AUC) and
confidence interval were calculated for each gene respectively
based on at least 90% specificity (Figure 3; Table 3). The
methylation quantity over cut-off points were considered as
hypermethylation per gene to calculate the methylation frequency
in all studied cases (Table 4). As blood-based marker, our designed
panel could cover 91.7% of the plasma samples (92.6% for early
stage and 88.9% for late stage of breast cancer) and also covered
95% of serum samples (91.7% for early stage and 100% for late
stage of breast cancer) (Table 4).
Relationship between promoter methylation and
clinicopathological parameters
In this study, associations between the promoter methylation of
the 10 studied genes in cfDNA of breast cancer patients and
clinicopathological parameters, such as age, histological grade,
pathologic stage, lymph node involvement and receptor status
were analyzed (Dataset S3).
In plasma samples, promoter hypermethylation of GSTP1 gene
was significantly correlated with higher age ($50), hypermethyla-
tion of P16 gene was correlated with pathologic early stage of
cancer and hypermethylation of BMP6 gene was correlated with
lymph node involvement (P,0.05) (Dataset S3). In normal cases,
there was no significant correlation between methylation propor-
tion of candidate genes and clinicopathological parameters.
In triple matched samples, promoter hypermethylation extent of
four TSGs in serum samples showed correlation with clinical
parameters (APC with histological grade G2; BMP6 and CST6 with
lymph node involvement; TIMP3 with pathological late stage and
lymph node involvement) (P,0.05) (Dataset S3).
Comparison of methylation proportion with recognition
sites of well-known transcription factor regions
The methylation proportion and localization of each CpG site
in the range of 2400 to +200 was schematically compared to the
Table 3. ROC curve analysis of plasma and serum samples based on methylation proportion of the 10 genes.
Sample type Genes
Specificity
(%)
Sensitivity
(%) AUC
*
Asymptotic 95%
confidence interval
(Lower - Upper Bound)
Cut-off points**
(methylation
quantification)
Plasma APC 90 50 0.824 0.720–0.928 0.42
BIN1 90 53 0.776 0.665–0.888 0.67
BMP6 90 30 0.631 0.493–0.768 0.71
BRCA1 90 75 0.874 0.780–0.967 0.57
CST6 90 56 0.718 0.592–0.843 0.58
ESR-b (ER beta) 90 31 0.611 0.471–0.752 0.76
GSTP1 90 35 0.712 0.585–0.838 0.66
P16 (CDKN2A) 90 50 0.732 0.608–0.856 0.91
P21 (CDKN1A) 90 88 0.965 0.915–1.000 0.65
TIMP3 90 35 0.761 0.640–0.882 0.68
Serum APC 90 25 0.814 0.676–0.951 0.46
BIN1 90 40 0.757 0.608–0.907 0.69
BMP6 90 45 0.795 0.647–0.943 0.93
BRCA1 90 60 0.854 0.730–0.977 0.70
CST6 90 75 0.870 0.809–0.991 0.53
ESR-b (ER beta) 90 30 0.595 0.409–0.781 0.92
GSTP1 90 40 0.581 0.393–0.769 0.43
P16 (CDKN2A) 90 40 0.710 0.546–0.874 0.69
P21 (CDKN1A) 90 25 0.709 0.540–0.877 0.66
TIMP3 90 35 0.717 0.557–0.878 0.48
*AUC: area under the curve.
**Cut-off points were calculated according to 90% specificity.
doi:10.1371/journal.pone.0016080.t003
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sites for regulatory enhancers, CAAT box, GC box, transcription
factor II-B recognition elements, TATA box, initiation site of
transcription and downstream promoter elements) for the both
cohorts (Fig. 4).
Hypermethylated CpG sites in the plasma sample from breast
cancer patients were almost located between TATA box and initiator,
however, in plasma of normal subjects hypermethylated CpGs were
randomly distributed and did not show significant association between
location of the CpG sites and conserved sequences (Fig. 4a).
The analysis of triple matched samples revealed that the
hypermethylated CpG sites in tumor tissue and serum samples
were mostly located in a range of 240 to +1 (TATA box and
initiator) and 226 to +1 (TATA box), respectively. While in
normal samples the CpG sites were differentially methylated and
located randomly in the 59UTRs of the studied genes (Fig. 4b).
Discussion
In this study, we assessed the methylation proportion of more
than 31,248 CpG sites on 10 breast cancer candidate genes in 126
different samples consisting of two different cohorts. Using
hierarchical clustering in the plasma samples cohort, we found
significant promoter hypermethylation of eight genes (APC, BIN1,
BRCA1, CST6, GSTP1, P16, P21 and TIMP3) in patients’ plasma
of breast cancer patients compared with plasma of normal subjects
(Fig. 2a). To proof that hypermethylation pattern in plasma
cfDNA of breast cancer patients is derived from tumor tissue,
triple matched samples including breast cancerous tissue, matched
normal tissue and serum samples were analyzed. Two-way
hierarchical clustering in serum and tumor tissue showed
significant hypermethylation patterns of seven genes (APC, BIN1,
BMP6, BRCA1, CST6, P16 and TIMP3) compared with normal
tissue (Fig. 2b; Dataset S1). This data revealed the potential of the
candidate genes for developing a blood-based test as a predictive
and prognostic biomarker for breast cancer.
The pathway analysis showed the involvement of the 10
candidate genes in cell cycle and DNA repair (BRCA1, P16 and
P21), invasion and metastasis (CST6 and TIMP3), cell proliferation
(ESR-b), signal transduction (APC, BIN1 and BMP6) and cell
detoxification (GSTP1), and highlighted their role in breast
carcinogenesis. Approximately one-third of the differentially
Table 4. Frequency and coverage of promoter methylation in plasma and serum cfDNA.
Type of tumor Promoter methylation frequency in plasma Promoter methylation frequency in serum
Genes
Methylation
frequency Coverage
a Genes
Methylation
frequency Coverage
a
Samples with early stage*
of cancer
APC 48.1% 92.6% APC 25% 91.7%
BIN1 55.6% BIN1 41.7%
BRCA1 48.1% BRCA1 58.3%
CST6 55.6% CST6 41.7%
GSTP1 29.6% GSTP1 8.4%
P16 (CDKN2A) 59.2% P16 (CDKN2A) 41.7%
P21 (CDKN1A) 40.7% P21 (CDKN1A) 16.7%
TIMP3 33.3% TIMP3 25%
Samples with late stage**
of cancer
APC 44.4% 88.9% APC 25% 100%
BIN1 44.4% BIN1 12.5%
BRCA1 55.5% BRCA1 12.5%
CST6 44.4% CST6 12.5%
GSTP1 22.2% GSTP1 75%
P16 (CDKN2A) 22.2% P16 (CDKN2A) 37.5%
P21 (CDKN1A) 33.3% P21 (CDKN1A) 37.5%
TIMP3 22.2% TIMP3 62.5%
All analyzed samples APC 47.2% 91.7% APC 25% 95%
BIN1 52.8% BIN1 30%
BRCA1 50% BRCA1 40%
CST6 52.8% CST6 30%
GSTP1 27.8% GSTP1 35%
P16 (CDKN2A) 50% P16 (CDKN2A) 40%
P21 (CDKN1A) 38.9% P21 (CDKN1A) 25%
TIMP3 30.6% TIMP3 40%
aCoverage: percentage of cases with methylation in at least one gene in the given panel (i.e., coverage of 100% means that all samples had methylation of at least one
gene in the panel).
*The pathologic stage,III was considered as ‘‘Early stage’’.
**The pathologic stage III and IV was considered as ‘‘Late stage’’.
doi:10.1371/journal.pone.0016080.t004
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normal tissue [17,21]. Similarly, present study showed accumu-
lation of hypermethylated CpG sites of 10 studied genes nearby
TATA box and initiator (240 to +1) in the cancerous and serum
samples, however, in normal samples the CpG sites were
differentially methylated and located randomly in the 59-UTRs
(Fig. 4). This data verified that hypermethylation of critical part of
promoter regions might be the major mechanism for transcription
alterations leading to silencing or down regulation of candidate
genes. Also hypermethylation of several genes in the same pathway
might contribute to tumor aggressiveness.
It has been estimated that more than 90% of the total
circulating cfDNA is derived from tumor tissue [22,23]. Several
studies reported tumor related genetic and epigenetic alterations in
serum and plasma cfDNA of breast cancer patients [24,25,26,27],
but studies comparing methylation patterns in tumor and serum
DNA in early or late stages of breast tumorigenesis are limited.
According to the origin of plasma or serum cfDNA which is
released during cell necrosis or apoptosis, it appears that serum
tends to contain more DNA than plasma. However, some of this
DNA in serum could be due to DNA contamination derived from
leukocytes [28]. In our study, there was significant concordance
regarding the methylation patterns of seven analyzed genes in
serum sample with tumor tissue (Dataset S1 & 2). This result
suggested that cancer specific methylation changes in plasma and
serum could be used in developing blood-based tests, which could
be applied for risk assessment, earlier diagnosis and monitoring of
cancers.
Methylation changes in the process of tumorigenesis are often
very heterogeneous and still no single gene has been found to be
methylated in all breast cancer types. Therefore it is necessary to
use a panel of genes as biomarkers to screen certain type of cancer.
Different studies have shown a wide range of gene panels
according to the frequently methylated genes in different type of
cancer including breast cancer. The coverage and sensitivity of
reported panels to detect different types of breast cancer, ranges
from 40 to 90% depended on the selected genes
[10,17,26,29,30,31,32,33]. In the recent study, applying the eight
genes panel could achieve to 91.7% of coverage in sensitive
methylation quantification for plasma and 95% for serum samples
with more than 90% specificity in both studied cohorts (Table 4).
The variability of the reported gene panels in different studies
makes it difficult to compare or combine them and to interpret
how promoter methylation would serve as biomarker [34]. The
inclusion of genes that may have a key role in breast cancer might
help to improve the specificity of a gene panel. Our finding
highlights the necessity of using different genes in one panel which
increases the coverage of detected cases nearly to 100% (Table 4).
Figure 4. Comparison of the mean methylation proportion and approximate position of informative CpG sites in the range of 2400
to +200 according to the recognition sites of the transcription factors in the 10 candidate genes. A) Comparison of methylation
proportion in 36 plasma samples of breast cancer patients and 30 plasma samples of normal subjects. B) Comparison of methylation proportion in 60
triple samples (cancerous breast tissue, matched normal tissue and serum samples) from 20 breast cancer patients. (Dots in the map are
corresponding to the mean methylation quantity of each CpG site in all analyzed cases).
doi:10.1371/journal.pone.0016080.g004
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candidate genes in plasma of breast cancer patients and
clinicopathological parameters revealed significant correlation of
GSTP1 hypermethylation with higher age ($50), P16 hypermethy-
lation with early stage of breast cancer and BMP6 with lymph
node involvement. In the serum samples, promoter hypermethyla-
tion of some studied genes was correlated with clinical parameters
(APC with histological grade G2; TIMP3 with late stage of breast
cancer; BMP6, CST6, and TIMP3 with lymph node involvement)
(Dataset S3). This data might require further validation by using
bigger sample size cohorts.
Technically, we quantified methylation proportion of the candi-
date genes in cfDNA derived from plasma and serum using T-
cleavage assay on MALDI-TOF MS. According to the origin of
cfDNA in plasma or serum which is released during cell necrosis or
apoptosis, the majority of isolated cfDNA should be poor with regard
to quantity and quality and it is difficult to deal with long amplicons
for further downstream experiments [5,18,35]. We could overcome
this limitation of dealing with fractionated, low concentrated and
poor quality DNA, using a specialized re-amplification strategy for
performing high-throughput methylation analysis on MALDI-TOF
MS based on our established method [18].
Presented data is promising to design a gene panel and develop
a blood-based screening method for breast cancer which relies on
pathologic methylation changes. Tissue specific and blood-based
methylation markers might provide valuable information as
prognostic and predictive markers for breast cancer, as well as
for developing novel targeted therapeutic strategies.
Additional information
The complete data for high-throughput methylation analysis of
informative CpG sites in 10 breast cancer-related genes, including:
gene location, amplicon size and two-way hierarchical cluster
analysis of two different studied cohorts are illustrated in dataset
S1. Scatterplot Matrix (SPLOM) analysis and correlation of the
methylation extent of DNA from different are summarized in
dataset S2. Correlation study between promoter methylation
extent and clinicopathological parameters is shown in dataset S3.
Supporting Information
Dataset S1
N Double dendrogram of analyzed genes: Two-way hierarchical
cluster analysis of 36 plasma samples from breast cancer
patients and 30 plasma samples of normal subjects.
N Comparison of informative CpG sites in two groups of plasma
samples.
N Double dendrogram of analyzed genes: Two-way hierarchical
cluster analysis of 60 triple samples (breast cancerous tissue,
matched normal tissue serum and samples) from 20 breast
cancer patients.
(PDF)
Dataset S2
N Scatterplot Matrix (SPLOM) analysis for mean methylation
proportion of 10 genes in triple samples from 20 breast cancer
patients (breast cancerous tissue, matched normal tissue and
serum samples).
N Correlation study of the mean methylation proportion of
informative CpG sites for ccfDNA in serum versus tumor and
normal samples (S: Serum, N: Normal, T: Tumor).
N Scatterplot Matrix (SPLOM) analysis for mean methylation
proportion of 10 genes in 36 plasma samples of breast cancer
patients and 30 plasma samples of normal subjects.
(PDF)
Dataset S3
N Correlation study between promoter methylation of 10 studied
genes and clinicopathological parameters in 36 plasma and 20
serum samples.
(PDF)
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